Higher semaglutide dose approved in USA

medwireNews: Semaglutide will soon be available at a dose of 2.0 mg in the USA, following FDA approval.

The weekly injectable glucagon-like peptide-1 receptor agonist was previously approved at a maximum dose of 1.0 mg, as used in the main SUSTAIN trial series.

But the more recent SUSTAIN-FORTE trial showed the 2.0 mg dose to produce a significantly larger reduction in glycated hemoglobin than the 1.0 mg dose, forming the basis of this approval.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group